Forecyte Bio Opens CGT Production Facility in Maryland

Forecyte Bio, a provider of cell and gene therapy contract development and manufacturing, opened its 17,000 sq.-ft., state-of-the-art cGMP facility. 
 
The new production facility consists of individual cleanroom suites for plasmid DNA, viral vectors and cell therapies, as well as lab space for process development and quality control testing. They are equipped with state-of-the-art bioreactors and purification apparatus such as XDR-200 and AKTA Ready to support programs for cell and gene therapies.
 
“We are very proud to be able to complete the cGMP facility with such speed and quality,” said Dr. Yujian You, the General Manager of Forecyte Bio USA, “This great milestone is just the beginning for Forecyte. We will partner with cell and gene therapy developers to offer our 4x4TM CGT CDMO services to accelerate their product development with speed, agility, and quality from concept to patients.”